cAMP responsive element binding protein 5Genealiases: CRE-BPA · CREB-5 · CREBPA
Q-omics provides the consensus-scored CREB5 profile across patient tissues and cancer cell-line models. CREB5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CREB5 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CREB5 RNA expression shows 19,098 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where CREB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CREB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CREB5 survival associations across molecular data types. CREB5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CREB5 RNA expression–survival associations across cancer types. High CREB5 expression shows unfavorable associations in UVM, MESO, BLCA, LGG and LUAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CREB5 RNA expression.
This table summarizes CREB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CREB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CREB5 shows lower tumor expression in BLCA and BRCA and higher tumor expression in KIRC, KIRP, HNSC and THCA. The KIRC box plot shows higher CREB5 RNA expression in tumor versus normal tissue (log2 FC = +1.662, t-test p < 0.001).
This table shows molecular features associated with CREB5 in patient tissues and cancer cell lines. In patient samples, CREB5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CREB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
